参考文献/References:
[1] Guleria A,Duseja A,Kalra N,et al.Patients with non-alcoholic fatty liver disease(NAFLD)have an increased risk of atherosclerosis and cardiovascular disease[J].Trop Gastroenterol,2013,34(2):74-82.
[2] Monsalve FA,Pyarasani RD,Delgado-Lopez F, et al.Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases[J].Mediators Inflamm,2013(2013):549627.
[3] Fiévet C, Staels B. Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease[J].Curr Atheroscler Rep,2009,11(4):281-288.
[4] Lalloyer F,Staels B.Fibrates, glitazones, and peroxisome proliferator-activated receptors[J].Arterioscler Thromb Vasc Biol,2010,30(5):894-899.
[5] Staels B,Rubenstrunk A,Noel B, et al.Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J].Hepatology,2013,58(6):1941-1952.
[6] Chanda D,Lee CH,Kim YH, et al.Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner[J].Hepatology,2009,50(3):880-892.
[7] Fiorucci S,Antonelli E,Rizzo G, et al.The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis[J].Gastroenterology,2004,127(5):1497-1512.
[8] Bieghs V,Van Gorp PJ,Wouters K, et al.LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease[J].PLoS One,2012,7(1):e30668.
[9] Shiri-Sverdlov R,Wouters K,van Gorp PJ, et al.Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates[J].J Hepatol,2006,44(4):732-741.
[10] Linden MA,Fletcher JA,Morris EM, et al.Combining metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in OLETF rats[J].Am J Physiol Endocrinol Metab,2014,306(3):E300-E310.
[11] Hahm JR,Ahn JS,Noh HS, et al.Comparative analysis of fat and muscle proteins in fenofibrate-fed type Ⅱ diabetic OLETF rats: the fenofibrate-dependent expression of PEBP or C11orf59 protein[J].BMB Rep,2010,43(5):337-343.
[12] Cariou B,Zair Y,Staels B, et al.Effects of the new dual PPAR alpha/delta agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism[J].Diabetes Care,2011,34(9):2008-2014.
[13] Trottier J,Perreault M,Rudkowska I, et al.Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate[J].Clin Pharmacol Ther,2013,94(4):533-543.
[14] Wheeler MC,Gekakis N.Hsp90 modulates PPARγ activity in a mouse model of nonalcoholic fatty liver disease[J].J Lipid Res,2014,55(8):1702-1710.
[15] Zhang W,Wu R,Zhang F, et al.Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway[J].Clin Exp Pharmacol Physiol,2012,39(12):1026-1033.
[16] Zheng H,Li S,Ma L, et al.A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance[J].Eur J Pharmacol,2011,659(2-3):244-251.
[17] Yang L,Stimpson SA,Chen L, et al.Effectiveness of the PPARγ agonist, GW570, in liver fibrosis[J].Inflamm Res,2010,59(12):1061-1071.
[18] Kakiuchi-Kiyota S, Vetro JA, Suzuki S, et al. Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse[J].Toxicol Appl Pharmacol,2009,237(1):83-90.
[19] Ratziu V,Charlotte F,Bernhardt C, et al.Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy(FLIRT 2)extension trial[J].Hepatology,2010,51(2):445-453.
[20] Sathyanarayana P,Jogi M,Muthupillai R, et al.Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes[J].Obesity(Silver Spring),2011,19(12):2310-2315.
[21] Iwaisako K,Haimerl M,Paik YH, et al.Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist[J].Proc Natl Acad Sci U S A,2012,109(21):E1369-E1376.
[22] Barroso E,Astudillo AM,Balsinde J, et al.PPARβ/δ activation prevents hypertriglyceridemia caused by a high fat diet. involvement of AMPK and PGC-1α-Lipin1-PPARα pathway[J].Clin Investig Arterioscler,2013,25(2):63-73.
[23] Kostadinova R,Montagner A,Gouranton E, et al.GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation[J].Cell Biosci,2012,2(1):34.
[24] Sahebkar A,Chew GT,Watts GF.New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease[J].Expert Opin Pharmacother,2014,15(4):493-503.
[25] Bays HE,Schwartz S,Littlejohn T, et al.MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin[J].J Clin Endocrinol Metab,2011,96(9):2889-2897.
[26] Ban S, Kasuga JI, Nakagome I, et al. Structure-based design, synthesis, and nonalcoholic steatohepatitis(NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor(PPAR)α-selective agonists[J].Bioorg Med Chem,2011,19(10):3183-3191.
相似文献/References:
[1]胡雅琴,包玉倩.维生素D对非酒精性脂肪性肝病的保护作用[J].国际内分泌代谢杂志,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
Hu Yaqin,Bao Yuqian..Protective effect of vitamin D on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(06):408.[doi:10.3760/cma.j.issn.1673-4157.2014.06.013]
[2]聂秀玲,李明珍,孙丽荣.高尿酸血症与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2016,36(02):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
Nie Xiuling,Li Mingzhen,Sun Lirong..Hyperuricemia and non-alcoholic fatty liver[J].International Journal of Endocrinology and Metabolism,2016,36(06):89.[doi:10.3760/cma.j.issn.1673-4157.2016.02.004]
[3]张洁,邸阜生.运动防治非酒精性脂肪性肝病的机制[J].国际内分泌代谢杂志,2016,36(06):404.[doi:10.3760/cma.j.issn.1673-4157.2016.06.12]
Zhang Jie,Di Fusheng..Mechanism of exercise on non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2016,36(06):404.[doi:10.3760/cma.j.issn.1673-4157.2016.06.12]
[4]张雅楠,郗光霞,杨翠萍,等.自噬在非酒精性脂肪性肝病中的变化及作用[J].国际内分泌代谢杂志,2017,37(01):11.[doi:10.3760/cma.j.issn.1673-4157.2017.01.03]
Zhang Yanan*,Xi Guangxia,Yang Cuiping,et al.The change and function of autophagy in nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2017,37(06):11.[doi:10.3760/cma.j.issn.1673-4157.2017.01.03]
[5]李博,苏青.晚期糖基化终末产物及其受体与非酒精性脂肪性肝病的
关系[J].国际内分泌代谢杂志,2017,37(03):192.[doi:10.3760/cma.j.issn.1673-4157.2017.03.013]
Li Bo,Su Qing..Relationship between advanced glycation end-products and its receptor in nonalcoholic fatty liver diseases[J].International Journal of Endocrinology and Metabolism,2017,37(06):192.[doi:10.3760/cma.j.issn.1673-4157.2017.03.013]
[6]狄红杰,刘超.饮食干预对非酒精性脂肪性肝病肠道菌群的影响[J].国际内分泌代谢杂志,2017,37(04):254.
Di Hongjie,Liu Chao..Effects of diet interventions on gut microbiota of nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2017,37(06):254.
[7]林楚曼 林伟浩 周蕊 杨力.GLP-1缓解非酒精性脂肪性肝病相关信号通路的研究进展[J].国际内分泌代谢杂志,2018,38(03):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
Lin Chuman*,Lin Weihao,Zhou Rui,et al.The research progresses on GLP-1 related signal pathways in alleviating non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(06):179.[doi:10.3760/cma.j.issn.1673-4157.2018.03.009]
[8]李霞 雷涛.铁过载与代谢性疾病的关系[J].国际内分泌代谢杂志,2018,38(01):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
Li Xia*,Lei Tao..Relationship between iron overload and metabolic diseases[J].International Journal of Endocrinology and Metabolism,2018,38(06):29.[doi:10.3760/cma.j.issn.1673-4157.2018.01.008]
[9]曹白鸽 董艳.母体妊娠期高脂饮食所致的炎性反应状态对子代的影响[J].国际内分泌代谢杂志,2018,38(02):96.[doi:10.3760/cma.j.issn.1673-4157.2018.02.006]
Cao Baige*,Dong Yan..Effects of inflammatory state on offspring induced by maternal high-fat diet during pregnancy[J].International Journal of Endocrinology and Metabolism,2018,38(06):96.[doi:10.3760/cma.j.issn.1673-4157.2018.02.006]
[10]于晓蕾 陈新卫 任路平.骨形态发生蛋白与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2018,38(02):128.[doi:10.3760/cma.j.issn.1673-4157.2018.02.015]
Yu Xiaolei*,Chen Xinwei,Ren Luping.Bone morphogenetic protein and non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2018,38(06):128.[doi:10.3760/cma.j.issn.1673-4157.2018.02.015]